OpenURL Connection Search

Select item for more details and to access through your institution.

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Published in:
American Journal of Hematology, 2024, v. 99, n. 2, p. E63, doi. 10.1002/ajh.27180
By:
- Karrar, Omer;
- Abdelmagid, Maymona;
- Rana, Masooma;
- Iftikhar, Moazah;
- McCullough, Kristen;
- Al‐Kali, Aref;
- Alkhateeb, Hassan B.;
- Begna, Kebede H.;
- Elliott, Michelle A.;
- Mangaonkar, Abhishek;
- Saliba, Antoine;
- Hefazi Torghabeh, Mehrdad;
- Litzow, Mark R.;
- Hogan, William;
- Shah, Mithun;
- Patnaik, Mrinal M.;
- Pardanani, Animesh;
- Badar, Talha;
- Murthy, Hemant;
- Foran, James
Publication type:
Article
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Published in:
American Journal of Hematology, 2024, v. 99, n. 2, p. 193, doi. 10.1002/ajh.27138
By:
- Gangat, Naseema;
- Karrar, Omer;
- Iftikhar, Moazah;
- McCullough, Kristen;
- Johnson, Isla M.;
- Abdelmagid, Maymona;
- Abdallah, Mostafa;
- Al‐Kali, Aref;
- Alkhateeb, Hassan B.;
- Begna, Kebede H.;
- Mangaonkar, Abhishek;
- Saliba, Antoine N.;
- Hefazi Torghabeh, Mehrdad;
- Litzow, Mark R.;
- Hogan, William;
- Shah, Mithun;
- Patnaik, Mrinal M.;
- Pardanani, Animesh;
- Badar, Talha;
- Murthy, Hemant
Publication type:
Article
Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients.
Published in:
Annals of Hematology, 2024, v. 103, n. 3, p. 957, doi. 10.1007/s00277-023-05612-9
By:
- Heybati, Kiyan;
- Ochal, Domenic;
- Hogan, William;
- Al-Khateeb, Hassan;
- Sklar, David;
- Herasevich, Svetlana;
- Litzow, Mark;
- Shah, Mithun;
- Torghabeh, Mehrdad Hefazi;
- Durani, Urshila;
- Bauer, Philippe;
- Gajic, Ognjen;
- Yadav, Hemang
Publication type:
Article
Prognostic Significance of Early Declines in Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation.
Published in:
Respiratory Care, 2023, v. 68, n. 10, p. 1406, doi. 10.4187/respcare.10925
By:
- Yadav, Hemang;
- Torghabeh, Mehrdad Hefazi;
- Hogan, William J.;
- Limper, Andrew H.
Publication type:
Article

Found: 4

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.

Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients.

Prognostic Significance of Early Declines in Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation.